跳至主要内容
临床试验/ISRCTN73316039
ISRCTN73316039已完成3 期

Serenoa repens, lycopene and selenium vs. phosphodiesterase type 5 inhibitor (PDE5 inhibitor) for the treatment of lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH): the Sprite study

Konpharma SR0 个研究点目标入组 600 人开始时间: 2015年5月22日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
600

研究概览

研究设计

研究类型
Interventional

入排标准

性别
Male

入选标准

  • 1. Age between 50 and 75
  • 2. Digital rectal examination negative for prostate cancer
  • 3. Prostate specific antigen (PSA) <4ng/ml
  • 4. IPSS =12
  • 5. PVR <100 ml
  • 6. Peak flow between 4 and 15ml/s

排除标准

  • 1. Prostate cancer, previous bladder cancer, diabetes mellitus, neurogenic disorders, severe liver
  • disease, history of orthostatic hypotension or syncope, symptomatic urinary tract infection.
  • 2. Antiandrogens, antidepressants (neuroleptics, anticholinergics) therapy, recent treatment with an
  • a blocker (within 1 month) or phytotherapy including saw palmetto extract (within 3 months),
  • previous medical therapy with 5ARI, PDE-5i or surgical treatment for LUTS/BPH.
  • 3. Patients with catheter or with an episode of acute retention of urine in the last 3 months

研究者

发起方
Konpharma SR

相似试验